Submitted By: StephDiStef on Jul 7, 2014
Scheduled on Nov 1, 2014
2014 Over the Edge for Brain Cancer
Participants Rappel 365 ft. from the Manchester Grand Hyatt to raise critical funding for brain tumor research in San Diego, CA
Watch event video here: youtu.be/f8fbQIjoXko
| || Rappel 365 ft. in San Diego to support brain cancer research! |
When: Saturday, November 1, 2014; 8:00 a.m. – 6:00 p.m.
Where: Manchester Grand Hyatt; 1 Market Place, San Diego, CA 92101
What: Over the Edge for Brain Cancer is a unique and exciting opportunity in which participants or “edgers” rappel down the Manchester Grand Hyatt San Diego, the tallest building on the waterfront! Edgers raise a minimum of $1,500 to participate, and all event proceeds benefit San Diego-based brain cancer research. With only 20 rappel spots still available, your opportunity to participate will be gone before you know it! Visit www.otesandiego.org
to register or sign-up to volunteer today!
Why: Brain cancer is a disease that often doesn’t receive the attention it deserves, which leads to a dangerous lack in awareness and funding.
Brain cancer is:
• the second leading cause of cancer deaths among children and young adults.
• extremely heterogeneous, with 120 different types of tumors, all of which have unknown causes.
• not as rare as you might think. Today there are more than 600,000 people in the US living with a brain tumor diagnosis and another 66,000 new diagnosis are expected this year.
Who: Before November 1, 2014: Participants interested in rappelling or volunteering are encouraged to sign-up by September 5, 2014.
On November 1, 2014: Spectators and the general public are invited to celebrate the day with our fearless edgers, and enjoy food, fun and fitness vendors all day! We will be raffling one spot to go Over the Edge at 3:00 p.m. on November 1, 2014. Must be present to win.
About Accelerate Brain Cancer Cure
Accelerate Brain Cancer Cure (ABC2) is a venture philanthropy 501(c) (3) nonprofit organization that drives cutting-edge research and treatments for brain tumors. Through strategic partnerships with medical research centers, early-stage biotechnology companies and large multi-national pharmaceutical companies ABC2 has awarded more than $20 million in brain tumor research funding to highly qualified investigators and physician-scientists from 42 institutions and companies. For more information, please visit: www.abc2.org